Drugs for Relapse Prevention of Alcoholism

Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several neurochemical pathways in the brain and furthermore that an imprinted drug and addiction memory may scarcely be extinguished. Hence, the question arises as to whether there ought to be a reasonable hope that pharmacological drugs will be developed that interfere with an addiction memory, and as a result, finally lead to a cure? In this book, leading preclinical and clinical experts in the field of alcohol relapse prevention strive to furnish an answer to this question. None of the researchers or clinicians believes in a magic bullet that will be of help to all alcoholic patients in overcoming this disease. However, there is now convi- ing evidence demonstrating that specific subpopulations of alcoholic patients experience satisfactory benefit from currently available treatments. Today we have two medications for relapse prevention on the market - acamprosate and naltrexone. Although, currently, only a minority of alcoholic patients benefit from these medications, the approval of these compounds may be considered a hallmark in the field of psychopharmacology, even comparable to the era when the first antidepressant compounds were introduced. In recent years we have been witnessing an enormous growth in the science and knowledge regarding the field of relapse prevention.

"The field of biomedical research on alcoholism has developed at an astonishing speed in recent years. Today, new medications and treatment strategies are available and new leads are currently tested in multi-center trials. This book gives a comprehensive overview about different neurotransmitter/peptide systems involved in craving and relapse behavior and critically describes the clinical application of new anti-craving and anti-relapse compounds. The editors - a preclinical researcher and a clinical researcher, together with some of the most distinguished experts in the field - compiled the most recent available preclinical and clinical data, offering a thorough picture on modern relapse prevention. Undoubtedly, this book sets out to provide an all-encompassing overview about the topic, which will be of interest to the preclinical researcher, the clinician as well as to the patient who wants to learn more. TOC:From the contents:History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabus): the first medication to stop drinking.- Naltrexone: preclinical and clinical data.- Acamprosate: preclinical and clinical data.- Serotonergic compounds: preclinical and clinical data.- Opioidergic compounds: preclinical and clinical data.- Glutamatergic compounds: preclinical and clinical data.- Dopaminergic compounds: preclinical and clinical data.- Baclofen: preclinical and clinical data.- Cholinergic compounds: preclinical and clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: preclinical data.- The future of relapse prevention"

History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabuse®): the first medication to stop drinking.- Naltrexone: preclinical data.- Naltrexone: clinical data.- Acamprosate: preclinical data.- Acamprosate: clinical data.- Serotonergic compounds: preclinical data.- Serotonergic compounds: clinical data.- Opioidergic compounds: preclinical data.- Second generation opioidergic compounds: clinical data.- Dopaminergic compounds: preclinical data.- Dopaminergic compounds: clinical data.- Baclofen: preclinical data.- Baclofen: clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: a perspective.- Future perspectives on relapse prevention.